Group items tagged

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy. Published March 4 in the New England Journal of Medicine*, data from the double-blind, randomized, comparative clinical trial fill a large information gap in the treatment of childhood absence epilepsy, also known as "petit mal" epilepsy. The research, which identifies important differences between drugs in seizure control and side effects, is expected to impact how physicians select and monitor initial therapy for children with the disorder and ultimately lead to improved outcomes.

Study to assess the development and neurological status of all children who were diagnosed as "mild ventriculomegaly" during the pregnancy in the last 6 years and to prospectively follow up all the children who will be diagnosed from the beginning of the study on for 6 years.

The Hospital for Sick Children study is to determine whether infants with triventricular hydrocephalus (TVH) have a better long-term outcome at 5 years when they are treated with a new procedure, endoscopic third ventriculostomy (ETV), than infants treated with the more traditional treatment, insertion of a cerebrospinal fluid (CSF) shunt.

To evaluate the safety and multi-dose pharmacokinetics and dose ranging of intravenous followed by enteral myo-inositol (inositol) given at three dosage levels in extremely preterm neonates.

The Hydrocephalus Foundation, Inc. (HyFI) is a registered, 501(c)(3) nonprofit organization dedicated to providing support, educational resources and networking opportunities to patients and families affected by hydrocephalus. The Foundation also promotes related research and facilitates the training of healthcare professionals to improve patient outcome.

The Agency for Healthcare Research and Quality (AHRQ) is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. AHRQ is a home to research centers that specialize in major areas of health care research such as quality improvement and patient safety, outcomes and effectiveness of care, clinical practice and technology assessment, and health care organization and delivery systems. Source of funding and technical assistance for health services research and research training at leading U.S. universities and other institutions, as well as a science partner, working with the public and private sectors to build the knowledge base for what works-and does not work-in health and health care and to translate this knowledge into everyday practice and policymaking.

Study is to determine whether nerve growth factor (cerebrolysin®) therapy will improve the psychomotor outcome in infants with moderate and severe hypoxic ischemic encephalopathy.

The National Hydrocephalus Foundation (NHF) was incorporated in the state of Illinois in 1979 as a voluntary, not-for-profit, 501 C (3), public service organization. The objectives of NHF are: To assemble and disseminate information pertaining to hydrocephalus, its treatments and outcomes To establish and facilitate a communication network among affected families and individuals To help others gain a deeper understanding of those areas affected by hydrocephalus, such as education, insurance, tax and estate planning, employment and family To increase public awareness and knowledge of hydrocephalus To promote and support research on the causes, treatment and prevention of hydrocephalus